Randomised clinical trial : yoga vs written self‐care advice for ulcerative colitis
Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT‐0401 and REVERSE randomised clinical studies
Polycystic ovary syndrome with hyperandrogenism as a risk factor for non‐obese non‐alcoholic fatty liver disease
A nomogram for predicting prognostic value of inflammatory response biomarkers in decompensated cirrhotic patients without acute‐on‐chronic liver failure
Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin
Chenodeoxycholic acid stimulated fibroblast growth factor 19 response – a potential biochemical test for bile acid diarrhoea.
A visual analogue scale and a Likert scale are simple and responsive tools for assessing dysphagia in eosinophilic oesophagitis
Diagnostic features of malignancy‐associated pseudoachalasia
Performing routine follow‐up biopsy 1 year after diagnosis does not affect long‐term outcomes in coeliac disease
Editorial : sorafenib toxicity, a biomarker of effect?
Editorial : sorafenib toxicity, a biomarker of effect? Authors’ reply
Editorial : the impact of the placebo effect in Crohn's disease
Editorial : the impact of the placebo effect in Crohn's disease – author's reply
Editorial : anti‐tumour necrosis factor α antibodies – can efficacy be regained?
Editorial : anti‐tumour necrosis factor α antibodies – can efficacy be regained? Authors' reply
Editorial : variability in adalimumab trough and peak serum concentrations
Editorial : variability in adalimumab trough and peak serum concentrations – authors’ reply
Editorial : risk factors for persistent villus atrophy in coeliac disease – is it time to reconsider definitions for refractory coeliac disease?
Editorial : risk factors for persistent villus atrophy in coeliac disease – is it time to reconsider definitions for refractory coeliac disease? Authors' reply